The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Issue 3 (20th May 2020)

• Record Type: Journal Article
• Authors: Pelletier, Ryan; Ng, Kelvin; Alkabbani, Wajd; Labib, Youssef; Mourad, Nicolas; Gamble, John‐Michael
• Is Part Of: Endocrinology, diabetes & metabolism. Volume 3:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-05-20
• Subjects: adverse events -- cancer -- overview of reviews -- SGLT2 inhibitors -- type 2 diabetes -- umbrella reviews; Endocrinology -- Periodicals; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1002/edm2.145
• Languages: English
• ISSNs: 2398-9238

Abstract

Abstract: Aims: To summarize reported cancer events associated with SGLT‐2 inhibitors used in patients with type 2 diabetes mellitus, as well as assess the quality of included reviews. Materials and methods: In May 2019, we searched PubMed, Embase and the Cochrane Library for quantitative systematic reviews assessing the safety of SGLT‐2 inhibitors. Data were abstracted using a standardized form, and methodological quality was assessed using the AMSTAR 2 tool. Main outcome measures included total cancer events and specific cancers such as breast cancer, bladder cancer, gastrointestinal cancer, prostate cancer, respiratory cancer, renal cancer and skin cancer. Pooled treatment effects from included reviews were summarized for SGLT‐2 inhibitors as a class and for individual SGLT‐2 inhibitors commonly used worldwide (canagliflozin, dapagliflozin and empagliflozin). Results: We screened 1248 unique citations, of which eight quantitative systematic reviews meta‐analysed results from studies reporting the association between an SGLT‐2 inhibitor and any cancer. Only one review was rated as high quality according to AMSTAR 2 assessment. In total, data from 170 cancer‐related point estimates (PE) were reported. As a class, SGLT‐2 inhibitors were not associated with an increased risk of any cancer event versus placebo and active comparators. Most point estimates (7/143) were nonsignificant for individual cancers except for two associations. Empagliflozin was associated with an increased risk of bladder cancer versus placebo and active comparators in two reviews, while canagliflozin appeared protective for gastrointestinal cancer versus placebo and active comparators in one review. Conclusions: It appears that SGLT‐2 inhibitors are not associated with an increased risk of total cancer or specific cancers in patients with type 2 diabetes. However, higher quality evidence is needed to derive confident conclusions. Abstract : The association of sodium glucose cotransporter 2 (SGLT2) inhibitors with cancer has been reported in several quantitative systematic reviews. Most quantitative systematic reviews addressing cancer risk in patients with type 2 diabetes mellitus are of low quality (according to AMSTAR2 assessment). From the available evidence, it appears that SGLT2 inhibitors are not associated with an increased or decreased risk of total cancer events, or specific cancers, in patients with type 2 diabetes.